Abstract: The present invention relates to dexmecamylamine and the use of dexmecamylamine, substantially free of exo-R-mecamylamine, in the treatment of bladder disorders, including overactive bladder.
Abstract: Compositions containing calcium citrate malate wherein the calcium citrate malate exhibits one or more of: a pore area of at least about 30 m2/g; a dissolution rate of at least about 95% by weight of the calcium citrate malate in less than about 120 seconds.
Type:
Grant
Filed:
August 17, 2007
Date of Patent:
November 18, 2014
Assignee:
The Procter & Gamble Company
Inventors:
Ashok Premchand Luhadiya, Timothy William Dake, Glenn Richard Hudepohl, Donald Brown Compton
Abstract: A storage stable aqueous solution of amifostine at a pH of at least 10.0, in an amifostine concentration of about 50 to about 250 mg/l, which formulation is storage stable under refrigerated conditions.
Abstract: The present invention relates to a compound of formula (I): The compound has apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and is thus useful in the treatment of diseases such as kidney disease, diabetic nephropathy and kidney fibrosis.
Abstract: Embodiments of the invention include compositions effective for inhibiting collagen production and related methods. A preferred method comprises contacting at least one cell capable of producing collagen with a composition effective for inhibiting collagen production thereby. The composition comprises one or more of the compounds effective for inhibiting collagen production disclosed herein.
Type:
Grant
Filed:
October 5, 2012
Date of Patent:
May 20, 2014
Assignee:
The Florida State University Research Foundation, Inc.
Abstract: The present invention relates to a liquid composition containing an active substance belonging to the family of substituted benzhydryl piperazines with reduced amounts of preservatives.
Type:
Grant
Filed:
July 6, 2005
Date of Patent:
January 21, 2014
Assignee:
UCB Pharma, S.A.
Inventors:
Domenico Fanara, Jean Scouvart, Claire Poulain, Michel Deleers
Abstract: The present invention relates to substituted pyrazolo[4,3-h]quinazoline compounds which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity, in particular PIM kinases. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such these compounds or the pharmaceutical compositions containing them.
Type:
Grant
Filed:
December 16, 2011
Date of Patent:
September 24, 2013
Assignee:
Nerviano Medical Sciences SRL
Inventors:
Francesco Casuscelli, Claudia Piutti, Antonella Ermoli, Daniela Faiardi
Abstract: The present invention relates to piperazine dithioctate, a novel addition salt of thioctic acid with a base and a pharmaceutical composition comprising the same. The piperazine dithioctate according to the present invention has good thermal and moisture stability and high water-solubility as well as dosage increase lower than other addition salts, thereby being effectively used for preparing a pharmaceutical composition for antioxidation or for preventing or treating diabetic polyneuropathy, etc.
Type:
Grant
Filed:
June 18, 2010
Date of Patent:
September 24, 2013
Assignees:
Celltrion Chemical Research Institute, Celltrion Pharm, Inc.
Inventors:
Kyoung Soo Kim, Young Jun Park, Hyun-Nam Song, In Suk Lee, Joon Woo Kim
Abstract: Disclosed herein are novel antioxidant inflammation modulators, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds and compositions thereof are also provided.
Type:
Grant
Filed:
December 19, 2011
Date of Patent:
August 20, 2013
Assignee:
Reata Pharmaceuticals, Inc.
Inventors:
Eric Anderson, Gary L. Bolton, Bradley Caprathe, Xin Jiang, Chitase Lee, William H. Roark, Melean Visnick
Abstract: There is provided a salt of 1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridinyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid selected from the group consisting of citrate, hemi-fumarate, maleate, L-tartrate, mesylate, hydrochloride, potassium, and sodium salts.
Abstract: The present invention is directed to a compound of the formula: and pharmaceutically acceptable tautomers, or salts thereof which are inhibitors of syk and/or JAK kinase. The present invention is also directed to pharmaceutical compositions containing such a compound.
Type:
Grant
Filed:
January 30, 2012
Date of Patent:
August 6, 2013
Assignee:
Portola Pharmaceuticals, Inc.
Inventors:
Shawn M. Bauer, Zhaozhong J. Jia, Mukund Mehrotra, Yonghong Song, Qing Xu, Wolin Huang, Chandrasekar Venkataramani, Jack W. Rose, Anjali Pandey
Abstract: The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3K?. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
Type:
Grant
Filed:
January 13, 2012
Date of Patent:
June 18, 2013
Assignee:
Vertex Pharmaceuticals Incorporated
Inventors:
Alex Aronov, Jon H. Come, Robert J. Davies, Albert Charles Pierce, Philip N. Collier, Ronald Lee Grey, Jr., Hardwin O'Dowd, James A. Henderson, Elaine B. Krueger, Arnaud Le Tiran, Yusheng Liao, David Messersmith, Jian Wang, Suganthini S. Nanthakumar, Jingrong Cao, Upul Keerthi Bandarage, Anne-Laure Grillot
Abstract: The present invention relates to the discovery of new class of hydrolysable amino acid derivatives and absorbable polyester amides, polyamides, polyepoxides, polyureas and polyurethanes prepared therefrom. The resultant absorbable polymers are useful for drug delivery, tissue engineering, tissue adhesives, adhesion prevention, bone wax formulations, medical device coatings, stents, stent coatings, highly porous foams, reticulated foams, wound care, cardiovascular applications, orthopedic devices, surface modifying agents and other implantable medical devices. In addition, these absorbable polymers should have a controlled degradation profile.